Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
β-conglycinin is a **soy-derived storage protein fraction** found in soybeans and soy protein isolate, generally regarded as a functional food ingredient rather than a conventional pharmaceutical drug. In human studies, orally administered β-conglycinin has been investigated as a nutraceutical ingredient for **hypertriglyceridemia, visceral adiposity, obesity, and broader lifestyle-related metabolic disorders**. Its proposed mechanism is not a single receptor-ligand pharmacology; instead, it appears to act as a **dietary protein/nutraceutical** that can improve lipid metabolism and reduce serum triglycerides and visceral fat, likely through metabolic and hepatic lipid-handling effects associated with soy protein consumption. The provided randomized placebo-controlled study used β-conglycinin-containing candy and reported reductions in serum triglycerides and visceral fat versus casein control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on β-conglycinin.